Devonian Health Group Inc. has announced the granting of a substantial number of stock options to its directors and employees, a move aimed at enhancing its corporate strategy and rewarding its team. On December 19, 2025, the biopharmaceutical company, based in Quebec, revealed that its Board of Directors has approved the issuance of 2,948,056 stock options.
Of this total, 2,798,056 options were allocated to the company’s directors, while the remaining 385,950 options were designated for employees as part of their performance bonuses and retention efforts. Additionally, 100,000 options were granted to a research and development consultant. The stock options are exercisable at a price of $0.18 per share and will remain valid for ten years from the grant date.
The vesting schedule for the options includes an initial 25% vesting on the grant date, followed by an additional 25% vesting each year for the subsequent three years for certain employees and consultants. This structure aims to align the interests of directors, employees, and consultants with the long-term success of the company.
Innovative Products and Corporate Strategy
Devonian is focused on developing prescription drugs for inflammatory diseases, with its flagship product, Thykamine™, emerging from its proprietary SUPREX™ platform. Thykamine™ is designed to prevent and treat various health conditions related to inflammation and oxidative stress, including ulcerative colitis, atopic dermatitis, and rheumatoid arthritis. The product’s efficacy has been supported by numerous in vitro and in vivo studies, along with successful Phase II clinical trials demonstrating its potential in treating patients with mild-to-moderate conditions.
The company holds patents for both Thykamine™ and the SUPREX™ platform in several regions, including North America, Europe, and Asia, underscoring its commitment to protecting its innovations and intellectual property.
Corporate Overview and Market Position
Founded in 2015, Devonian Health Group Inc. operates at the clinical stage of pharmaceutical development, specializing in novel therapeutic approaches for autoimmune inflammatory conditions. The company has established a strong foundation of research spanning over 15 years, aligning its strategies with regulatory guidelines from the U.S. Food and Drug Administration that favor efficient pathways for the development of botanical drug products.
In addition to its pharmaceutical endeavors, Devonian is also active in the cosmeceutical sector, leveraging its proprietary methodologies to develop high-value products. The company owns a subsidiary, Altius, dedicated to the commercialization of prescription pharmaceutical products in Canada, working under licenses from established pharmaceutical brands.
Devonian Health Group Inc. is publicly traded on both the TSX Venture Exchange (TSXV: GSD) and the OTCQB Venture Market (OTCQB: DVHGF), reflecting its active engagement in the capital markets as it pursues its strategic objectives.
As the company navigates the challenges of the biopharmaceutical landscape, the recent grant of stock options is a clear signal of its dedication to incentivizing its team while positioning itself for future growth.
